Reporting remotely on findings presented at AACR 2020 Virtual Meeting, Lajos Pusztai comments on important breast cancer studies.
He firstly presents results from the I-SPY 2 trial evaluating the addition of olaparib to immune checkpoint inhibitors in high-risk, HER2-negative, locally advanced breast cancer. He then comments on two presentations of the EMBRACA trial on the effect of talazoparib on overall survival in patients with advanced, HER2-negative breast cancer with a germline BRAC1/2 mutation, and on the impact of tumour BRCA zygosity and genomic loss-of-heterozygosity as a biomarker for patient selection.
• CT011 - Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL (Lajos Pusztai, USA)
• CT071 - Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial (Jennifer Litton, USA)
• CT072 - Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2−) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation (Lida Mina, USA)